

SUPPLEMENTARY MATERIAL
TABLES

Supplementary Table 1. Baseline patient characteristics.

Parameter	N=25
Women, No. (%)	13 (52)
Mean (SD) age, y	53.7 (12.3)
Mean (SD) body mass index	26.6 (8.7)
Smoking (n=24)	
Never smoker, No. (%)	16 (66.7)
Ex-smoker, No. (%)	7 (29.1)
Smoker, No. (%)	1 (4.2)
Age at onset symptoms (n=22)	
0-18 y, No. (%)	5 (22.7)
>18 y, No. (%)	17 (77.3)
Atopy, No. (%)	15 (60)
Rhinosinusitis, No. (%) (n=24)	20 (83.3)
Nasal polyps, No. (%) (n=24)	15 (62.5)
Polyposis surgery (n=15)	
Once	9 (60)
More than once	3 (20)
Mean (SD) SNOT-22	62.8 (30.0)
Food allergy	1 (4)
Atopic dermatitis	3 (12)
Corticosteroid-dependent, No. (%)	9 (36)
Mean (SD) oral prednisone (or equivalent) dose, mg/d	13.6 (3.8)
Mean (SD) eosinophils	491.6 (386.9)
Mean (SD) IgE	698.5 (1406.0)
Mean (SD) FeNO	46.3 (25.7)
Mean (SD) ACT	13.2 (4.1)
Mean (SD) AQLQ	3.6 (1.2)
Mean (SD) Exacerbations	3.4 (2.1)
≥1 Emergency department visit, No. (%) (n=23)	12 (52.2%)
Mean (SD) FVC, L	3.22 (1.05)
Mean (SD) FVC %	78.7 (16.0)
Mean (SD) FEV ₁ , L	2.27 (0.76)
Mean (SD) FEV ₁ , %	69.1 (15.9)
Mean (SD) prior treatment with a biologic agent	
Omalizumab, No. (%)	5 (20)
Mepolizumab, No. (%)	4 (16)
Benralizumab, No. (%)	1 (4)

Abbreviations: ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Test; FeNO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in the first second; FVC, forced vital capacity.

Supplementary Table 2. Results.

	Patients with oral corticosteroids at baseline (n=9)				
	Baseline (n=9)	4 wk (n=7)	P Value ^a	12 wk (n=7)	P Value ^a
Median (IQR) oral prednisone (or equivalent) dose, mg/d	15 (10-15)	10 (5-15)	.063	7.5 (5-10)	.039
	Patients with nasal polyps (n=15)				
	Baseline (n=15)	4 wk (n=13)	P Value ^a	12 wk (n=12)	P Value ^a
Median (IQR) SNOT-22 ^b	59 (46-69)	34 (14-48)	.002	21 (12-30)	.005
Median (IQR) Meltzer ^b	4 (2-6)	NA	NA	0 (0-1.5)	.02

Abbreviation: NA, not available.

^aWilcoxon signed rank test.

^bOnly patients with polyposis were considered.